GGrantIndex
← Leaderboards

Sudhir Paul

University Of Texas Hlth Sci Ctr Houston

Google Scholar ↗PubMed ↗ORCID ↗
$10,174,455
Attributed
$10,174,455
Total exposure
11
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY2005–17
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$12,324,090 · 12

By mechanism

R01$6,901,923 · 6
P01$2,283,847 · 2
U01$2,033,990 · 1
R21$1,104,330 · 3

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Hlth Sci Ctr Houston

Same institution · by research overlap

Others in their field

Top investigators on “Immunization”

Research focus

ImmunizationBaseSpecificityPropertyAntibodiesReactionCatalystBinding (Molecular Function)AbzymeResponsePeptidesB-LymphocytesAlzheimer&AposSiteHiv Envelope Protein Gp120Laboratory MouseAnalogEpitopesAntigensMonomerAffinityComplexLibrariesGenetic Library

Grant awards (36)

Tau-directed catalytic antibodies$192,500
R21 · FY2017 · NS · contact PI
Tau-directed catalytic antibodies$231,000
R21 · FY2016 · NS · contact PI
Efficacious and safe antibody catalyzed amyloid beta clearance$1
U01 · FY2014 · AG · contact PI
Efficacious and safe antibody catalyzed amyloid beta clearance$482,995
U01 · FY2013 · AG · contact PI
Efficacious and safe antibody catalyzed amyloid beta clearance$511,111
U01 · FY2012 · AG · contact PI
Efficacious and safe antibody catalyzed amyloid beta clearance$511,110
U01 · FY2011 · AG · contact PI
Nucleophilic Antibodies: Characterization and Induction$454,376
R01 · FY2011 · AI · contact PI
Efficacious and safe antibody catalyzed amyloid beta clearance$528,773
U01 · FY2010 · AG · contact PI
Nucleophilic Antibodies: Characterization and Induction$459,600
R01 · FY2010 · AI · contact PI
Nucleophilic Antibodies: Characterization and Induction$450,717
R01 · FY2009 · AI · contact PI
Nucleophilic Antibodies: Characterization and Induction$437,589
R01 · FY2008 · AI · contact PI
beta-Amyloid Antibodies with Specific Proteolytic Activity$362,558
R01 · FY2008 · AG · contact PI
gp120 covalent analogs as candidate HIV vaccines$319,526
R01 · FY2008 · AI · contact PI
Nucleophilic Antibodies: Characterization and Induction$445,198
R01 · FY2007 · AI · contact PI
beta-Amyloid Antibodies with Specific Proteolytic Activity$359,183
R01 · FY2007 · AG · contact PI
gp120 covalent analogs as candidate HIV vaccines$325,715
R01 · FY2007 · AI · contact PI
Proteolytic Antibody HIVcides$206,558
R21 · FY2007 · AI · contact PI
beta-Amyloid Antibodies with Specific Proteolytic Activity$359,134
R01 · FY2006 · AG · contact PI
gp120 covalent analogs as candidate HIV vaccines$335,444
R01 · FY2006 · AI · contact PI
Proteolytic Antibody HIVcides$177,272
R21 · FY2006 · AI · contact PI
beta-Amyloid Antibodies w/ Specific Proteolytic Activity$369,275
R01 · FY2005 · AG
gp120 covalent analogs as candidate HIV vaccines$343,516
R01 · FY2005 · AI
gp120 covalent analogs as candidate HIV vaccines$355,641
R01 · FY2004 · AI
INNATE AND Ag-ADAPTED CHEMICALLY REACTIVE ANTIBODIES$297,000
R21 · FY2003 · AI
CATALYTIC HIV ANTIBODIES$737,260
P01 · FY2002 · AI
RECOMBINANT SINGLE DOMAIN &HYBRID PEPTIDASE ANTIBODIES$227,958
R01 · FY2002 · AI
Elicitation of HIV specific catalystic immunity$0
P01 · FY2002 · AI
CATALYTIC HIV ANTIBODIES$716,342
P01 · FY2001 · AI
CATALYTIC ANTIBODIES FOR TUMOR IMMUNOTHERAPY$298,763
R01 · FY2001 · CA
RECOMBINANT SINGLE DOMAIN &HYBRID PEPTIDASE ANTIBODIES$221,320
R01 · FY2001 · AI
Elicitation of HIV specific catalystic immunity$0
P01 · FY2001 · AI
CATALYTIC HIV ANTIBODIES$696,033
P01 · FY2000 · AI
CATALYTIC ANTIBODIES FOR TUMOR IMMUNOTHERAPY$290,062
R01 · FY2000 · CA
CATALYTIC VIP AUTOANTIBODIES$271,473
R01 · FY2000 · HL
RECOMBINANT SINGLE DOMAIN &HYBRID PEPTIDASE ANTIBODIES$214,875
R01 · FY2000 · AI
Elicitation of HIV specific catalystic immunity$134,212
P01 · FY2000 · AI